Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 and up

Imaging of the intestinal and central lymphatic system with 18F-FTHA

Official title: INVESTIGATION OF A POSITRON-EMITTING LONG-CHAIN FATTY ACID (18F-FTHA), FOR IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM

Run by University of Pennsylvania · NCT07645573 · Data updated 2026-11-12

This study tests an oral radioactive tracer (18F-FTHA) to see how well it can visualize the lymphatic system in healthy adults and in people suspected of having a thoracic duct obstruction.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment25 (estimated)
SponsorUniversity of Pennsylvania
Academic / other
Drugs / interventionsradiation
Locations1 site (Philadelphia, Pennsylvania)
StatusRecruiting
StartedOctober 10, 2025
Main results expectedJune 30, 2028
Study endsJune 30, 2029
Registry record updatedAugust 6, 2026
Trial IDNCT07645573 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults 18 years and older for the volunteer cohort; adults 18 years and older with suspected thoracic duct–venous junction obstruction for the patient cohort.

Probably not a fit

Patients with non-obstructive conditions or those not undergoing TD-related procedures may not directly benefit from this imaging tracer.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In the first year, researchers will develop and optimize the 18F-FTHA tracer and test it in healthy volunteers. In the second year, the tracer will be used in patients with suspected thoracic duct obstruction to assess its imaging performance. Participants will fast, receive the tracer orally, and undergo dynamic PET/CT imaging for up to four hours, with a follow-up imaging session after any surgical bypass procedures if performed. The study includes a healthy volunteer cohort and a patient cohort with suspected TD-venous junction obstruction, with standard-of-care follow-ups as applicable. This is an early-phase interventional study focusing on tracer feasibility and imaging characteristics.

Why it matters

Potential benefit: If successful, the tracer could improve noninvasive visualization of the lymphatic system and help guide diagnosis and management of TD-related obstructions.

How similar studies have gone: Previous work in lymphatic imaging with novel PET tracers has shown feasibility, but this specific 18F-FTHA approach for TD imaging is investigational.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Inclusion Criteria (Healthy Volunteer Cohort)

1. Male and female participants will be ≥ 18 years of age.
2. "Healthy Volunteer" is defined for the purposes of this study as a volunteer who is in good general health in the opinion of an investigator (some well controlled chronic medical conditions may be allowed at the discretion of an investigator if they do not believe they will interfere with the collection of imaging data, specific excluded medical conditions are listed under exclusion criteria).
3. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Inclusion (Patient with suspected TD-venous junction obstruction cohort)

1. Male and female participants will be ≥ 18 years of age
2. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
3. Patient with chronic abdominal pain, ascites protein losing enteropathy, as well edema, with clinically suspected obstruction of the TD-venous junction and who are candidates for TD-venous junction plasty and or TD-Venous bypass

Exclusion Criteria:

Exclusion Criteria that apply to Healthy Volunteers only

1. Currently taking medication for cardiac disease, hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, and/or history of cardiac surgery per medical record review and/or self-report
2. Known history of liver or kidney disease per medical record review and/or self-report

Exclusion Criteria that applies to Healthy Volunteers and Patients:

1. Women who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential on the day of each of the PET/CT scans.
2. Subjects who report claustrophobia or Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
3. Self-reported difficulty with swallowing pills or allergy to components of Ensure Plus
4. Patients with a history of medical illness or disorder that in the opinion of an investigator and/or study physician could compromise patient safety or interfere with the collection of imaging data, or ability to complete the study and procedures, will be excluded.

Participant may not be involved in any other research studies involving ionizing radiation conducted within 1 year of their participation of this study.

Where it's running

  • University of Pennsylvania Hospital
    Philadelphia, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.